Akorn, Inc., a leading specialty pharmaceutical company, announced the launch of acetylcysteine injection 6 g/30 ml in 30 ml single-dose vials. Acetylcysteine injection is an intravenous antidote for the treatment of acetaminophen overdose.
The launch follows an approval of an Abbreviated New Drug Application (ANDA) for the product from the US Food and Drug Administration (FDA) on March 24, 2015.
Akorn's product is therapeutically equivalent to Acetadote injection marketed by Cumberland Pharmaceuticals Inc.
According to IMS Health, branded and generic sales of acetylcysteine injection were approximately $29 million for the twelve months ended May 31, 2015.